WASHINGTON, DC, January 13, 2014 — For the second consecutive year, Law360 has named Covington & Burling’s life sciences practice as one of the top five “Life Sciences Practice Groups of the Year.”
In a profile of the firm, Law360 noted that Covington “delivered for drugmakers on three continents in 2013, spearheading a momentous investment by U.K.-based AstraZeneca PLC, notching numerous litigation triumphs on U.S. soil and helping streamline product approvals in China.”
Among the matters highlighted by Law360 were Covington’s handling of a number of M&A and strategic partnering transactions. Law360 also recognized the firm’s strength in the litigation area, noting important successes on behalf of Johnson & Johnson, Salix, and Lilly in patent, commercial, and products liability cases. Finally, Law360 recognized the firm’s continued strength on the regulatory and public policy fronts, noting the firm’s involvement in efforts in China to update and harmonize China’s drug laws and its work domestically on various legislative and policy-making initiatives.
“We are honored to be selected as having one of the top life sciences practices,” said John Hurvitz, co-chair of the practice. “We are grateful for the confidence and trust our industry clients place in us each year and for the opportunities we have had to partner with them in navigating the increasingly-complex global life sciences marketplace – whether in the corporate, litigation, regulatory or other arenas.”
Law firms were selected for top honors based on the significance, size and complexity of the matters they handled for clients over the past year.
To read the complete profile, please click here.